Several previous studies have demonstrated that BRAF deletion mutations can occur in melanoma, pancreatic cancer, and thyroid cancer; in addition, activating BRAF deletion mutations might serve as a type of resistance mechanism to BRAF inhibitors plus MEK inhibitors (29–31). Here, BRAF is linked to thyroid gland carcinoma.